174 related articles for article (PubMed ID: 21519904)
21. Linking the T cell surface protein CD2 to the actin-capping protein CAPZ via CMS and CIN85.
Hutchings NJ; Clarkson N; Chalkley R; Barclay AN; Brown MH
J Biol Chem; 2003 Jun; 278(25):22396-403. PubMed ID: 12690097
[TBL] [Abstract][Full Text] [Related]
22. Making ends meet: the importance of the N- and C-termini for the structure, stability, and function of the third SH3 domain of CIN85.
Philippe D; Ababou A; Yang X; Ghosh R; Daviter T; Ladbury JE; Pfuhl M
Biochemistry; 2011 May; 50(18):3649-59. PubMed ID: 21446695
[TBL] [Abstract][Full Text] [Related]
23. Accurate characterization of weak macromolecular interactions by titration of NMR residual dipolar couplings: application to the CD2AP SH3-C:ubiquitin complex.
Ortega-Roldan JL; Jensen MR; Brutscher B; Azuaga AI; Blackledge M; van Nuland NA
Nucleic Acids Res; 2009 May; 37(9):e70. PubMed ID: 19359362
[TBL] [Abstract][Full Text] [Related]
24. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton.
Lynch DK; Winata SC; Lyons RJ; Hughes WE; Lehrbach GM; Wasinger V; Corthals G; Cordwell S; Daly RJ
J Biol Chem; 2003 Jun; 278(24):21805-13. PubMed ID: 12672817
[TBL] [Abstract][Full Text] [Related]
25. Targeting the SH3 domain of human osteoclast-stimulating factor with rationally designed peptoid inhibitors.
Han S; Liu Q; Wang F; Yuan Z
J Pept Sci; 2016 Aug; 22(8):533-9. PubMed ID: 27443979
[TBL] [Abstract][Full Text] [Related]
26. Solution structure of the first SH3 domain of human vinexin and its interaction with vinculin peptides.
Zhang J; Li X; Yao B; Shen W; Sun H; Xu C; Wu J; Shi Y
Biochem Biophys Res Commun; 2007 Jun; 357(4):931-7. PubMed ID: 17467669
[TBL] [Abstract][Full Text] [Related]
27. The SH3 domain of Eps8 exists as a novel intertwined dimer.
Kishan KV; Scita G; Wong WT; Di Fiore PP; Newcomer ME
Nat Struct Biol; 1997 Sep; 4(9):739-43. PubMed ID: 9303002
[TBL] [Abstract][Full Text] [Related]
28. Promiscuous binding nature of SH3 domains to their target proteins.
Agrawal V; Kishan KV
Protein Pept Lett; 2002 Jun; 9(3):185-93. PubMed ID: 12144515
[TBL] [Abstract][Full Text] [Related]
29. In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2.
Lehtonen S; Ora A; Olkkonen VM; Geng L; Zerial M; Somlo S; Lehtonen E
J Biol Chem; 2000 Oct; 275(42):32888-93. PubMed ID: 10913159
[TBL] [Abstract][Full Text] [Related]
30. Expression, refolding and crystallizations of the Grb2-like (GADS) C-terminal SH3 domain complexed with a SLP-76 motif peptide.
Faravelli A; Dimasi N
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Jan; 62(Pt 1):52-5. PubMed ID: 16511262
[TBL] [Abstract][Full Text] [Related]
31. Mislocalization or reduced expression of Arf GTPase-activating protein ASAP1 inhibits cell spreading and migration by influencing Arf1 GTPase cycling.
Liu Y; Yerushalmi GM; Grigera PR; Parsons JT
J Biol Chem; 2005 Mar; 280(10):8884-92. PubMed ID: 15632162
[TBL] [Abstract][Full Text] [Related]
32. Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55.
Le Bras S; Moon C; Foucault I; Breittmayer JP; Deckert M
FEBS Lett; 2007 Mar; 581(5):967-74. PubMed ID: 17306257
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for autoinhibition of the guanine nucleotide exchange factor FARP2.
He X; Kuo YC; Rosche TJ; Zhang X
Structure; 2013 Mar; 21(3):355-64. PubMed ID: 23375260
[TBL] [Abstract][Full Text] [Related]
34. Recognition of non-canonical peptides by the yeast Fus1p SH3 domain: elucidation of a common mechanism for diverse SH3 domain specificities.
Kim J; Lee CD; Rath A; Davidson AR
J Mol Biol; 2008 Mar; 377(3):889-901. PubMed ID: 18280496
[TBL] [Abstract][Full Text] [Related]
35. Regulation of the interaction between the neuronal BIN1 isoform 1 and Tau proteins - role of the SH3 domain.
Malki I; Cantrelle FX; Sottejeau Y; Lippens G; Lambert JC; Landrieu I
FEBS J; 2017 Oct; 284(19):3218-3229. PubMed ID: 28755476
[TBL] [Abstract][Full Text] [Related]
36. Atypical recognition consensus of CIN85/SETA/Ruk SH3 domains revealed by target-assisted iterative screening.
Kurakin AV; Wu S; Bredesen DE
J Biol Chem; 2003 Sep; 278(36):34102-9. PubMed ID: 12829691
[TBL] [Abstract][Full Text] [Related]
37. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS).
Gigante M; Pontrelli P; Montemurno E; Roca L; Aucella F; Penza R; Caridi G; Ranieri E; Ghiggeri GM; Gesualdo L
Nephrol Dial Transplant; 2009 Jun; 24(6):1858-64. PubMed ID: 19131354
[TBL] [Abstract][Full Text] [Related]
38. Solution structure of N-terminal SH3 domain of Vav and the recognition site for Grb2 C-terminal SH3 domain.
Ogura K; Nagata K; Horiuchi M; Ebisui E; Hasuda T; Yuzawa S; Nishida M; Hatanaka H; Inagaki F
J Biomol NMR; 2002 Jan; 22(1):37-46. PubMed ID: 11885979
[TBL] [Abstract][Full Text] [Related]
39. Molecular recognition properties of the C-terminal Sh3 domain of the Cbl associated protein, Cap.
Kurakin A; Hoffman NG; Kay BK
J Pept Res; 1998 Nov; 52(5):331-7. PubMed ID: 9894838
[TBL] [Abstract][Full Text] [Related]
40. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
